Shocking findings reveal NZ lagging behind in advanced breast cancer treatment

Images box

Breast Cancer Aotearoa Coalition media release, 7 September 2018

New Zealand needs to stop treating people with advanced breast cancer as second class citizens, Breast Cancer Aotearoa Coalition (BCAC) says.

The coalition of more than 30 breast cancer-related group says a report out today by the Breast Cancer Foundation of New Zealand (BCFNZ) reveals the shockingly high mortality rates for New Zealand women compared to other comparable countries.

Featured Article: 
Page Bars Setup: 

Media release: Plea for medicines funding

Images box

The Government must increase funding for medicines desperately needed by people with breast cancer and other cancers, Breast Cancer Aotearoa Coalition (BCAC) says.

“Women with breast cancer are going overseas, selling the family home and going into significant debt to get access to the medicines they need. A lot of women don’t have that option. This means if you have money or the ability to fundraise, you have a longer healthier life. That is a terrible inequity in our society today,” BCAC Chair Libby Burgess says.

Featured Article: 
Page Bars Setup: 

Sharing the latest on Australia & New Zealand breast cancer research

Images box

A wealth of knowledge has been brought back to New Zealand by two Breast Cancer Aotearoa Coalition representatives following the Breast Cancer Trials Australia New Zealand annual scientific meeting in Australia.

Committee members Louise Malone and Fay Sowerby attended to gather the latest intelligence to contribute to BCAC’s work supporting, informing and representing women with breast cancer.

Louise says it was impressive to see the huge amount of research underway and the big advances in understanding of breast cancer.

Featured Article: 
Page Bars Setup: 

Oncologists need a broader range of medicines in New Zealand

Images box

Recent international developments in breast cancer medicine approvals emphasise the need for a much broader range of medicines in New Zealand. Availability, combined with funding, would enable oncologists to choose the best medicines and combinations for individual patients, Breast Cancer Aotearoa Coalition (BCAC) says.

Featured Article: 
Page Bars Setup: 

Submission to PHARMAC requesting funding of Perjeta for all who need it

Images box

Breast Cancer Aotearoa Coalition and Breast Cancer Foundation NZ have made a strongly worded and evidence-based joint submission to PHARMAC requesting that funding for Perjeta (pertuzumab) be extended to all people with HER2-positive advanced breast cancer.

The submission was made to the Cancer Treatment Sub-committee (known as CaTSoP).  At its September meeting, CaTSoP will consider applications for funding for the following breast cancer medicines – Perjeta, Kadcyla, Ibrance, Abraxane, Faslodex.

Featured Article: 
Page Bars Setup: 

Meeting with decision makers to press for action to save and extend lives

Images box

Representatives of Breast Cancer Aotearoa Coalition (BCAC) went to Wellington recently to meet with Government and National MPs who have health responsibilities to discuss some of the key issues affecting those with breast cancer.

The two key issues highlighted by BCAC in the talks were the need to improve access to medicines; and the need to address inequities for Māori and Pasifika women in breast cancer screening and treatment.

Featured Article: 
Page Bars Setup: